Blog
Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.
Page 17
Do your genes affect incretin response?
Common variants in GLP1R and GIPR may shift weight loss outcomes and tolerability on semaglutide and tirzepatide, a 2026 review finds.
How Incretin Drugs Affect the Heart
A new review finds heart benefits from incretin drugs like tirzepatide and retatrutide involve pathways beyond blood sugar control.
Incretin Drugs and the Sarcopenia Question
A new review argues that incretin drugs such as tirzepatide and semaglutide need built-in muscle monitoring alongside fat-loss tracking.
Novo sues Lilly over GLP-1 ad claims
Novo Nordisk sued Eli Lilly over GLP-1 ads it says compare Zepbound with lower-dose Wegovy. Here is what the false-advertising suit alleges.
Is a 'research use only' peptide legal?
A research use only label on a peptide vial does not answer whether a clinic can legally give it to a patient.
Semaglutide and Alzheimer's after EVOKE
Semaglutide failed both EVOKE Alzheimer's trials. A new paper argues research should shift from one hypothesis to a stratified program.
Cold exposure and tirzepatide: mouse study
A mouse study found intermittent cold exposure did not add to tirzepatide's weight-loss effect in obese mice.
Tirzepatide and Oral Contraceptives
A new review asks whether tirzepatide's slowed digestion could also blunt oral progestogens used beyond birth control pills.
Tirzepatide vs GLP-1RAs and IBD risk
A US propensity-matched study found tirzepatide linked to fewer IV steroid courses than other GLP-1 drugs among patients who already have IBD.
What BPC-157 actually costs in the UK
BPC-157 has no UK licence, so there is no NHS price and no NICE appraisal. The only UK cost is grey-market research-chemical listings sold for research use.
Ipamorelin UK import rules for personal use
UK medicines law exempts personal imports from the manufacturer's licence rule, and that covers ipamorelin. Selling or advertising it is a separate question.
CT130: A GLP-1 Drug Built to Take Breaks
CT130 is a semaglutide-derived GLP-1 drug tested so far in mice and monkeys, not humans, built around scheduled drug-free intervals.